About Ataraxis AI
Ataraxis AI is an AI precision medicine company that develops AI-native diagnostics for oncology, helping physicians select the most effective cancer treatments. Its flagship product, Ataraxis Breast, is the first clinically validated AI-native prognostic and predictive platform for breast cancer, analyzing multi-modal patient data including pathology slides. The company's foundation model, Kestrel, is trained on hundreds of millions of pan-cancer pathology slide images and delivers results within 24 hours without exhausting physical tissue samples.
Company details
Funding
Total raised
$24.4M
Last stage
Series A
Investors
Founders
Jan Witowski
MD, PhD physician-scientist with over 10 years of medical image processing experience. Previously a postdoc at Harvard Medical School, Massachusetts General Hospital, and NYU Langone Health, where he led AI and medical imaging research.
LinkedIn
Krzysztof Geras
PhD machine learning scientist and Assistant Professor at NYU Grossman School of Medicine, Department of Radiology, also affiliated with NYU Center for Data Science and Courant Institute of Mathematical Sciences. Prior industry experience at JP Morgan, Microsoft, and Amazon.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.